NCT05369650

To Explore the Safety and Efficacy of Intravenous Infusion of Different Doses of Lidocaine in Patients

Status unknown NA Last updated 11 May 2022

What this trial tests

NA trial testing Lidocaine Hydrochloride, Injectable in Liver Cancer in 120 participants. Status unknown.

Timeline

27 July 2019

Primary endpoint
27 May 2022

27 September 2022

Quick facts

Lead sponsor	West China Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	120
Start date	27 July 2019
Primary completion	27 May 2022
Estimated completion	27 September 2022
Sites	1 location across China

Drugs / interventions tested

• Lidocaine Hydrochloride, Injectable — full drug profile →

Conditions studied

• Liver Cancer — all drugs for Liver Cancer →

Sponsor

West China Hospital

Who can join

Adults 18 to 70, any sex, with Liver Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

All patients who met the inclusion criteria were randomly divided into four groups, 30 cases in each group, which were lidocaine group 1, lidocaine group 1.5, lidocaine group 2, and the placebo group In lidocaine group 1, lidocaine group 1.5, and lidocaine group 2, 1% lidocaine 1.5 mg/kg was intravenously infused with a micropump after anesthesia induction, and the infusion was completed within 10 minutes according to the ideal body weight, and then continued for 1% lidocaine was infused at 1 mg/kg.h, 1.5 mg/kg.h and 2 mg/kg.h respectively until the end of the operation. In the placebo group, the same volume of normal saline was used instead.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.